华润双鹤：产品盐酸右哌甲酯缓释胶囊新进国家医保目录

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. has successfully negotiated the inclusion of its product, methylphenidate hydrochloride sustained-release capsules, into the National Medical Insurance Directory for 2025, under the category of Class B payment [1] Group 1 - The product is indicated for attention deficit hyperactivity disorder (ADHD) and cognitive enhancement [1] - The negotiation allows for the product to be reimbursed under the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance [1] - The agreement period for the negotiated drug is specified, indicating a structured approach to pricing and reimbursement [1]